Combined effects of C225 and 125-iodine seed radiation on colorectal cancer cells

Radiation Oncology

Junjie Wang²  Yong Zhao¹  Jinna Li²  Ang Qu²  Hao Wang²  Jingjia Liu² 

[1] Transplantation Biology Research Division, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China;Cancer Center, Peking University Third Hospital, Beijing, China

关键词: DNA-PK;    γ-H2AX;    DNA repair;    Apoptosis;    C225;   

Others  :  1152978
DOI  :  10.1186/1748-717X-8-219

 received in 2013-05-20, accepted in 2013-09-17,  发布年份 2013

【 摘 要 】

Background

To characterize the effect of combined treatment of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 and 125-iodine (¹²⁵I) seed radiation in human colorectal cancer.

Methods

We treated LS180 cells with ¹²⁵I continuous low dose rate radiation in the presence and absence of 100 nM C225. The clonogenic capacity, cellular proliferation, cell cycle distribution, apoptosis, and molecular pathways of the cells following the treatments were analyzed in vitro.

Results

The sensitizer enhancement ratio of C225 was approximately 1.4. Treatment with C225 and radiation alone produced significant inhibition of cell growth, but combination therapy produced greater inhibition than either treatment administered alone. C225 increased the radiation-induced apoptosis and the fraction of γ-H2AX foci positive cells at 48 h after treatment. The Akt phosphorylation level was lower in the cells receiving the combination treatment than in the cells treated with radiation or C225 alone.

Conclusions

These findings indicate that C225 sensitizes LS180 cells to ¹²⁵I seed radiation. Growth inhibition is mediated by inducing apoptosis and not cell cycle arrest. Additionally, we confirmed that C225 impairs DNA repair by reducing the cellular level of the DNA-PKcs and Ku70 proteins. Furthermore, the inhibition of Akt signaling activation may be responsible for the C225-mediated radiosensitization.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150.
• [2]Velenik V, Oblak I, Anderluh F: Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010, 5:88. BioMed Central Full Text
• [3]Smith JA, Wild AT, Singhi A, et al.: Clinicopathologic comparison of high-dose-rate endorectal brachytherapy versus conventional chemoradiotherapy in the neoadjuvant setting for resectable stages II and III Low rectal cancer. Int J Surg Oncol 2012, 2012:406568.
• [4]Vuong T, Devic S, Podgorsak E: High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol (R Coll Radiol) 2007, 19(9):701-705.
• [5]Sun Myint A, Mukhopadhyay T, Ramani VS, et al.: Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes? Colorectal Dis 2010, 12(Suppl 2):30-36.
• [6]Wang JJ, Yuan HS, Li JN, et al.: Interstitial permanent implantation of I-125 seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Colorectal Dis 2009, 24(4):391-399.
• [7]Meyn RE, Munshi A, Haymach JV, et al.: Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 2009, 92(3):316-322.
• [8]Chen DJ, Nirodi CS: The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007, 13(22 Pt 1):6555-6560.
• [9]Nyati MK, Morgan MA, Feng FY, et al.: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6(11):876-885.
• [10]Dale RG, Jones B: The clinical radiobiology of brachytherapy. Br J Radiol 1998, 71(845):465-483.
• [11]Kolotas C, Roddiger S, Strassmann G, et al.: Palliative interstitial HDR brachytherapy for recurrent rectal cancer, implantation techniques and results. Strahlenther Onkol 2003, 179(7):458-463.
• [12]Liang K, Ang KK, Milas L, et al.: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57(1):246-254.
• [13]Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
• [14]Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59(8):1935-1940.
• [15]Shrivastav M, De Haro LP, Nickoloff JA: Regulation of DNA double-strand break repair pathway choice. Cell Res 2008, 18(1):134-147.
• [16]Mao Z, Bozzella M, Seluanov A, et al.: Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008, 7(10):1765-1771.
• [17]Sedelnikova OA, Pilch DR, Redon C, et al.: Histone H2AX in DNA damage and repair. Cancer Biol Ther 2003, 2(3):233-235.
• [18]Takahashi A, Ohnishi T: Does gammaH2AX foci formation depend on the presence of DNA double strand breaks? Cancer Lett 2005, 229(2):171-179.
• [19]Banath JP, Klokov D, MacPhail SH, et al.: Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010, 10:4. BioMed Central Full Text
• [20]Choi EJ, Ryu YK, Kim SY, et al.: Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res 2010, 8(7):1027-1036.
• [21]Gupta AK, McKenna WG, Weber CN, et al.: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002, 8(3):885-892.
• [22]Harari PM, Wheeler DL, Grandis JR: Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009, 19(1):63-68.
• [23]Zhuang HQ, Wang JJ, Liao AY, et al.: The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res 2009, 28:12. BioMed Central Full Text
• [24]Wang J, Wang J, Liao A, et al.: The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. Cancer Biother Radiopharm 2009, 24(4):409-416.